Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Inhibition of ribosome biogenesis as a novel approach for multi-stage cancer treatment

Nearly ninety per cent of all cancer patient deaths are due to metastasis.

A study from Uppsala University shows that a process that allows the cells to metastasise is aided by the synthesis of new ribosomes, the cell components in which proteins are produced.

The results open the possibility for new treatment strategies for advanced cancers.

The study is published in Nature Communications.

As tumours progress towards advanced stages they dedifferentiate, become more aggressive and lose the characteristics of the origin tissue.

They also acquire the migratory capacity that allows the tumour to spread or metastasise to distant sites in the body, eventually causing patient death.

For epithelial tumours to metastasis the tumour cells undergo a process known as the epithelial-to-mesenchymal transition (EMT), which allows the cells to develop migratory ability.

During EMT, cells also lose their proliferative capacity and become more stem-like.

This remarkable transition leads to both increased invasiveness and an ability to evade numerous cancer treatments including hormonal therapies.

In the present study the researchers found that EMT is aided by the synthesis of new ribosomes, which serve to synthesise the proteins required for cell functions.

Their study therefore argues that ribosome biogenesis may be more than just a pro-proliferative process.

"Until recently, ribosomes have been considered to play only passive roles during the production of proteins. Our study shows that ribosomes potentially have complex, active roles and suggests that more attention should be given to understanding how ribosomes contribute to cell physiology in health and disease states," says Theresa Vincent, group leader at the Department of Immunology, Genetics and Pathology at Uppsala University, who has led the study together with Scott C. Blanchard at Weill Cornell Medicine, USA.

The researchers also demonstrated that by inhibiting the formation of new ribosomes, aggressive and hormone insensitive tumours could be partially reverted to a benign and non-metastatic type.

"We used a small molecule called CX-5461 to inhibit ribosome biogenesis in mouse models of human tumours. We found that primary tumours reverted from an invasive type to a non-invasive type as well as potentially regaining sensitivity to hormonal therapy. Importantly, CX-5461 treatment also resulted in a marked reduction of number lung metastases. This suggests that treatment with CX-5461 may enhance hormone therapy responsiveness in patients where this kind of treatment doesn't work any more. We find this to be a remarkable breakthrough and we are currently pursuing a number of additional validation studies," says Theresa Vincent.

Source: Uppsala University

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation